Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
1990-01-03 to 1990-04-30
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1990
Report date:
1990

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
EPA OPP 81-1 (Acute Oral Toxicity)
Version / remarks:
FIFRA: Pesticide Assessment Guidelines, Subdivision F; Hazard Evaluation: Human and Domestic Animals; Office of Pesticide Programs, U.S. Environmental Protection Agency, Office of Pesticide and Toxic Substances, Nov 1982; Sections 81-1, Acute Oral Toxicity Study

TSCA: Health Effects Test Guidelines: Office of Toxic Substances; Office of Pesticide and Toxic Substances. U.S. Environmental Protection Agency, Office of Pesticide and Toxic Substances, Aug 1982; Acute Exposure, Oral Toxicity
Deviations:
not specified
GLP compliance:
yes
Test type:
standard acute method

Test material

Constituent 1
Chemical structure
Reference substance name:
Phenol
EC Number:
203-632-7
EC Name:
Phenol
Cas Number:
108-95-2
Molecular formula:
C6H6O
IUPAC Name:
phenol
Constituent 2
Reference substance name:
1-chlorododecane
Molecular formula:
C12H25Cl
IUPAC Name:
1-chlorododecane
Constituent 3
Reference substance name:
1-Dodecanol
Cas Number:
112-53-8
Molecular formula:
C12H26O
IUPAC Name:
1-Dodecanol
Constituent 4
Reference substance name:
1-Tetradecanol
Cas Number:
112-72-1
Molecular formula:
C14H30O
IUPAC Name:
1-Tetradecanol
Constituent 5
Reference substance name:
triphenyl phosphate
Cas Number:
115-86-6
Molecular formula:
C18H15O4P
IUPAC Name:
triphenyl phosphate
Constituent 6
Chemical structure
Reference substance name:
-
EC Number:
431-760-5
EC Name:
-
Cas Number:
27460-02-2
Molecular formula:
C24H35O4P
IUPAC Name:
dodecyl diphenyl phosphate
Constituent 7
Chemical structure
Reference substance name:
diphenyl tetradecyl phosphate
Cas Number:
142474-86-0
Molecular formula:
C26H39O4P
IUPAC Name:
diphenyl tetradecyl phosphate
Constituent 8
Reference substance name:
Didodecyl phenyl phosphate
Cas Number:
56827-93-1
Molecular formula:
C30H55O4P
IUPAC Name:
Didodecyl phenyl phosphate
Test material form:
liquid

Test animals

Species:
rat
Strain:
Crj: CD(SD)
Sex:
male/female
Details on test animals or test system and environmental conditions:
10 CD®(Sprague-Dawley derived) young adult Albino rats (approx. 9-12 weeks old at study initiation; females were nulliparous and non-pregnant) were selected for this oral toxicity study. During the equilibration period of 12 days, all animals were checked for viability twice daily. Prior to assignment to study all animals were examined to ascertain suitability for study. Animals were randomly placed in cages upon receipt and were placed on study as available at the time of study initiation. Any animals considered unsuitable because of poor health or outlying body weights were excluded.
The animals were group-housed (6/cage) during the equilibration, and individually housed during the study in suspended, stainless steel with wire mesh bottoms. The room temperature was monitored and recorded twice daily and maintained between 67-76°F. The room humidity was recorded daily and maintained without 30-70%. The room had a light cycle of 12 hours light, 12 hours dark controlled by an automatic timer.
Purina Laboratory Chow and automatic watering system were served throughout the study.

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
unchanged (no vehicle)
Details on oral exposure:
A single dose was administrated to each animal, followed by 14 days of observation
Doses:
single oral dose of 5000 mg/Kg
No. of animals per sex per dose:
5/sex/dose
Control animals:
not specified
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Viability check twice daily, Pharmacologic and toxicologic signs observed for approximately 1, 2, and 4 hours after dosing and daily thereafter for 14 days. Body weights determined pre-fast, post-fast (just prior to dosing) and on days 7 and 14.
- Necropsy of survivors performed: yes. At termination all animals killed by carbon dioxide inhalation and examined grossly.

Results and discussion

Effect levels
Key result
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 5 000 mg/kg bw
Based on:
test mat.
Remarks on result:
not determinable due to absence of adverse toxic effects
Mortality:
All animals survived throughout the study.
Clinical signs:
other: Signs seen on the day of dosing included urinary and fecal staining, soft stool and evidence of oral discharge. One animal also had decreased food consumption on the day after dosing. All animals were free of any abnormalities from day 4 through terminati
Gross pathology:
Gross post-mortem observations were similar to those seen in control animals killed by carbon dioxide inhalation in this laboratory.

Any other information on results incl. tables

Table 2. Summary of Body Weights (g)

Animal Number

Pretest Weights

Day 7

Chga

Day 14

Chga

Pre-fast

Post-fast

Males

4532

262

237

272

10

305

43

4533

270

243

325

55

368

98

4541

272

248

323

51

359

87

4546

266

239

310

44

354

76

4549

283

257

332

49

359

31

Females

4573

218

202

235

17

249

31

4579

222

206

227

5

231

9

4584

223

208

230

7

242

19

4589

218

199

230

12

236

18

4591

232

208

253

21

264

32

a Change from prefasted weight (grams)

Table 3. Summary of pharmacologic and toxicologic signsa

Observations

Interval

Day

 

1

2

3

4-14

Hour

1

2

4

24

 

 

M/F

M/F

M/F

M/F

M/F

M/F

M/F

Dry oral discharge

1/-

-

-

-

-

-

-

Urinary staining

-

-

2/1

3/3

1/-

-/1

-

Fecal staining

1/-

2/1

4/2

3/2

-

-

-

Unthrifty coat

-

-

-

2/-

5/2

2/1

-

Soft stool

1/-

1/-

2/-

-

-

-

-

Food consumption decrease

-

-

-

1/-

-

-

-

a Number represent number of males and females (M/F), out of 5 per sex which exhibited signs one or more times during the interval

 

Table 4. Post-mortem observations – terminal necropsy (day 14)

Necropsy observations

Males

Females

4532

4533

4541

4546

4549

4573

4579

4584

4589

4591

External

No observable abnormalities

X

X

X

X

X

X

X

X

X

X

Internal

Red foci

a

a

a

a

a

a

a

a

a

a

Discolouration

a

a

a

a

a

a

a

a

a

A

Swollen uterus

 

 

 

 

 

 

 

X

 

X

a Changes considered due to carbon dioxide inhalation

X = observation present

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
Based on the lack of adverse treatment-related effects observed, the acute oral LD50 of XP-2563 in rats was determined to be greater than 5000 mg/Kg bw.
Executive summary:

A key Guideline EPA 81 -1 study was conducted to evaluate the oral toxicity of the test material (XP-2563) in rats. 10 young adult CD (Sprague-Dawley) derived rats received the test material as a single dose via oral gavage at 5000 mg/Kg. Pharmacologic and toxicologic signs were evaluated for at approximately 1, 2, and 4 hours after dosing and daily thereafter for 14 days. Body weights determined pre-fast, post-fast (just prior to dosing) and on days 7 and 14. At termination all animals were killed by carbon dioxide inhalation and examined grossly.

No mortality was observed through the study period and signs observed on the day of dosing included urinary and fecal staining, soft stool, and evidence of oral discharge. One animal was observed to have decreased food consumption on the day after dosing. All animals were free of any abnormalities from day 4 through termination of the study on day 14. Based on the lack of adverse treatment-related effects observed, the acute oral LD50 of XP-2563 in rats was determined to be greater than 5000 mg/Kg bw.